Jan 20, 2021

Featuring an interview with Dr Sagar Lonial on the following topics:

• Early versus late autologous stem cell transplant for newly diagnosed multiple myeloma (NDMM): Long-term follow-up analysis of the IFM 2009 trial
• Updated analysis of the GRIFFIN trial: Daratumumab with lenalidomide, bortezomib and dexamethasone for transplant-eligible patients with NDMM
• Phase III TOURMALINE-MM2 trial of oral ixazomib, lenalidomide and dexamethasone versus lenalidomide and dexamethasone for transplant-ineligible patients with NDMM
• Phase III APOLLO study evaluating the addition of subcutaneous daratumumab to pomalidomide and dexamethasone for patients with relapsed/refractory (R/R) MM
• Selinexor in combination with pomalidomide and dexamethasone for R/R MM
• Interim analysis of the IKEMA trial evaluating depth of response and response kinetics with isatuximab/carfilzomib/dexamethasone for R/R MM
• DREAMM-2: Single-agent belantamab mafodotin for patients with R/R MM; 1-year outcomes by prior therapy
• DREAMM-6: Safety, tolerability and clinical activity of belantamab mafodotin in combination with bortezomib/dexamethasone for R/R MM
• Updated results from the Phase I CRB-401 study investigating the B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy idecabtagene vicleucel for R/R MM
• CARTITUDE-1: A Phase IB/II study of the BCMA–directed CAR T-cell therapy ciltacabtagene autoleucel for R/R MM
• Updated results from the Phase I CRB-402 study of the anti-BCMA CAR T-cell therapy bb21217 for R/R MM
• Iberdomide in combination with dexamethasone and either daratumumab or bortezomib for patients with R/R MM
• Updated results from the Phase I trial of teclistamab, a BCMA x CD3 bispecific antibody for R/R MM
• Activity and safety of the bispecific antibodies talquetamab and BFCR4350A in patients with R/R MM
• ANCHOR trial: Updated efficacy and safety data with melflufen in combination with dexamethasone and either daratumumab or bortezomib for R/R MM
• KarMMa: Efficacy and safety of idecabtagene vicleucel in older patients with R/R MM
• Assessment of minimal residual disease by next-generation sequencing and FDG-PET/CT for patients with R/R MM treated with venetoclax, carfilzomib and dexamethasone

CME information and select publications